HR+/HER2- Advanced Breast Cancer and Endocrine Resistance
Status:
Recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
This is a randomized, 2-arm, open-label, multicenter, international phase II trial. A total
of 196 patients will be included.
The study will include patients with metastatic Hormone Receptor positive / Human Epidermal
Growth Factor Receptor (HER2) negative breast cancer with progressive disease after endocrine
treatment.
Patients will be randomized (1:1) between two treatment arms: A. palbociclib + fulvestrant
and b. capecitabine.